No connection

Search Results

NIVF vs ONCO

NIVF
NewGenIvf Group Limited
BEARISH
Price
$2.19
Market Cap
$1.2M
Sector
Healthcare
AI Confidence
95%
ONCO
Onconetix, Inc.
BEARISH
Price
$0.76
Market Cap
$0.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
NIVF
0.06
ONCO
--
Forward P/E
NIVF
0.23
ONCO
-0.9
P/B Ratio
NIVF
0.02
ONCO
0.02
P/S Ratio
NIVF
0.26
ONCO
0.67
EV/EBITDA
NIVF
-0.43
ONCO
0.73

Profitability

Gross Margin
NIVF
20.22%
ONCO
77.62%
Operating Margin
NIVF
-349.13%
ONCO
-422.06%
Profit Margin
NIVF
209.03%
ONCO
0.0%
ROE
NIVF
79.4%
ONCO
-115.46%
ROA
NIVF
-36.94%
ONCO
-14.93%

Growth

Revenue Growth
NIVF
11.9%
ONCO
-57.4%
Earnings Growth
NIVF
--
ONCO
--

Financial Health

Debt/Equity
NIVF
0.19
ONCO
0.0
Current Ratio
NIVF
3.12
ONCO
0.66
Quick Ratio
NIVF
0.82
ONCO
0.61

Dividends

Dividend Yield
NIVF
--
ONCO
--
Payout Ratio
NIVF
0.0%
ONCO
0.0%

AI Verdict

NIVF BEARISH

NIVF exhibits a catastrophic price collapse (-99.8% over 1 year) and severe operational dysfunction. While the Piotroski F-Score of 5/9 suggests baseline stability, this is heavily skewed by a non-operating profit spike, as evidenced by a 209.03% profit margin contrasted against a disastrous -349.13% operating margin. The company is fundamentally unable to generate profit from its core medical care facilities. The massive discrepancy between the current price ($2.19) and the single analyst's target price ($900) indicates a complete breakdown in valuation reliability.

Strengths
Low Debt/Equity ratio (0.19)
Strong Current Ratio (3.12) indicating short-term liquidity
Modest year-over-year revenue growth (11.90%)
Risks
Extreme operational losses (Operating Margin -349.13%)
Catastrophic price devaluation (-99.8% 1Y change)
Non-sustainable net income driven by non-operating gains
ONCO BEARISH

ONCO exhibits critical financial distress, anchored by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is in a catastrophic price collapse, falling from a 52-week high of $74.38 to $0.76, representing a near-total loss of market value. With a current ratio of 0.66 and revenue plummeting by 57.40% YoY, the firm faces an immediate liquidity crisis and a failing business model. The combination of extreme operating losses (-422.06% margin) and a bearish technical trend suggests a high probability of insolvency.

Strengths
High Gross Margin (77.62%) suggesting product value if costs were controlled
Low Price-to-Book ratio (0.02) indicating the stock trades far below book value
Low Price-to-Sales ratio (0.67)
Risks
Extreme liquidity risk with a Current Ratio of 0.66
Severe revenue contraction (-57.40% YoY)
Catastrophic price depreciation (-97.2% over 1 year)

Compare Another Pair

NIVF vs ONCO: Head-to-Head Comparison

This page compares NewGenIvf Group Limited (NIVF) and Onconetix, Inc. (ONCO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile